Presentazione di PowerPoint

1
Flow of Patients Through Trial
Nissen SE, et al. JAMA 20082991547-60
2
Baseline Characteristics of the Study Population
(n839)a
Nissen SE, et al. JAMA 20082991547-60
3
Body Weight, Waist Circumference, Metabolic
Outcomes, and Blood Pressure in Patients
Completing the Trial (n676)a
Nissen SE, et al. JAMA 20082991547-60
4
Effects of Rimonabant on Body Weight, Waist
Circumference, and Levels of HDL-C,
Triglycerides, Fasting Insulin, and Glycated
Hemoglobin (HbA1c)
Nissen SE, et al. JAMA 20082991547-60
5
Baseline, Follow-up, and Change from Baseline in
Intravascular Ultrasound End Points in Patients
Completing the Trial (n 676)
Nissen SE, et al. JAMA 20082991547-60
6
Primary Efficacy Parameter (Percent Atheroma
Volume) in Subgroups
Nissen SE, et al. JAMA 20082991547-60
7
Major Cardiovascular Adverse Events,
Treatment-Emergent Adverse Events, and Reasons
for Study Drug Discontinuation (Randomized
Population, n839)
Nissen SE, et al. JAMA 20082991547-60
8
Cumulative Incidence of Drug Discontinuation
Nissen SE, et al. JAMA 20082991547-60